SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced its participation in the Piper Sandler 32nd Annual Healthcare Conference to be held virtually December 1 – 3, 2020.
Hugh Young Rienhoff, Jr. M.D., chief executive officer of Imago BioSciences, will participate in a fireside chat with Christopher Andrews. The fireside chat will be pre-recorded and available on the Piper Sandler website to registered attendees beginning on Monday, November 23, 2020 at 10:00 am ET. The Company will host the one-on-one meetings with investors on Monday, November 30, 2020, meetings can be requested exclusively via Piper Sandler.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago BioSciences is backed by leading private, corporate, and public investors including Farallon Capital Management, LLC., funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by Blackrock Advisors, LLC., Surveyor Capital (a Citadel company), Irving Investors, Kingdon Capital Management, a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.
